

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **Hittinger et al.**

Examiner: Not yet known

Application No.: **10/773,806**

Art Unit: 1625

Filed: **February 6, 2004**

Title: **CHEMICAL DERIVATIVES AS ANTITELOMERASE AGENTS WHICH  
BIND SPECIFICALLY TO THE G-QUADRUPLEX DNA STRUCTURES  
AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

Listed reference DE 198 12 879 A1 is in the German language. Canadian publication No. 2 325 489 is an English language family member of DE 198 12 879 A1, and is believed to have substantially similar content as DE 198 12 879 A1.

Listed references DE 199 35 219 A1 and WO01/07020 are in the German language. U.S. Patent No. 6,362,210 B1 is an English language family member of DE 199 35 219 A1 and WO01/07020, and is believed to have substantially similar content as DE 199 35 219 A1 and WO01/07020.

Listed reference JP 11-60573, Masayuki et al., is in the Japanese language. An English language abstract of JP 11-60573 is provided herewith.

Listed reference JP 53-47439, Shizuo et al., is in the Japanese language. An English language abstract of JP 53-47439 is provided herewith.

Listed reference JP 6-49062, Katsutoshi et al., is in the Japanese language. An English language abstract of JP 6-49062 is provided herewith.

Listed reference Kreutzberger et al. is in the German language. An English language abstract of Kreutzberger et al. is provided herewith.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or any additional fees required by this paper or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

June 25, 2007

Date

Kelly L. Bender

Kelly L. Bender, Reg. No. 52,610  
Attorney for Applicant

Sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626  
Sanofi-Aventis Docket No. FRAV2003/0004 US NP



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet

2

○

4

**Complete if Known**

Application Number	10/773,806
--------------------	------------

<b>Filing Date</b>	02-06-2004
--------------------	------------

First Named Inventor	HITTINGER
----------------------	-----------

Group Art Unit	1625
----------------	------

Examiner Name	Not Yet Known
---------------	---------------

Attorney Docket Number	FRAV2003/0004 - US - NP
------------------------	-------------------------

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/773,806
				Filing Date	02-06-2004
				First Named Inventor	HITTINGER
				Group Art Unit	1625
				Examiner Name	Not Yet Known
Sheet	3	of	4	Attorney Docket Number	FRAV2003/0004 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BRATTAIN et al, Heterogeneity of Human Colon Carcinoma, Abstract of Cancer Metastasis Rev. 1984; 3(3):177-91	
		BURTON et al, Design of Novel Affinity Adsorbents for the Purification of trypsin-like Proteases, Abstract of J. Mol. Recognit. 1992, 5(2), pp. 55-68	
		CHEN et al, Spectroscopic Recognition of Guanine Dimeric Hairpin Quadruplexes by a Carbocyanine Dye, Proc. Natl. Acad. Sci. USA, Vol. 93, pp.2635-2639, April 1996	
		GILL, Surra. 3. Activity of Certain Derivatives of Acridine, Sulfonated Naphthylamine, aminoquinoline, styryl-quinoline, and Nitrofurazone Against Trypanosoma evansi in Rats, Abstract of Indian J. Anim. Sci., 1971, 41(6), pp. 503-9	
		HIRATANI et al, 2,6-Bis[N-(8-quinolyl)carbamoyl]pyridine as a Highly Selective Extractant for Cu(II), Bulletin of The Chemical Society of Japan, 1990, 63, pp. 3331-3333	
		KATSUTOSHI et al, Pyrimidinylamino- or Triazinylaminoquinoline Derivative and Its Production and Agricultural and Horticultural Germicide Containing the Same as Active Ingredient, Patent Abstracts of Japan, Publication No. 06049062 A, Publication Date Feb. 22, 1994	
		KREUTZBERGER et al, Synthesis And Spectroscopic Analyses Of Dianilinotriazines, English Language Abstract of Chemiker-Zeitung (1990, pp.208-210, volume 114)	
		KREUTZBERGER, ET AL, Synthesis And Spectroscopic Analyses Of Dianilinotriazines, Chemiker-Zeitung (1990, pp.208-210, volume 114)	
		MASAYUKI et al, Triazine Derivative and Telomerase Inhibitor, English Language Abstract of JP11-60573	
		MOKBEL et al, Telomerase and Breast Cancer: From Diagnosis to Therapy, Abstract of Int. J. Sug. Investig. 2000, 2(1), pp. 85-88	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/773,806		
		Filing Date	02-06-2004		
		First Named Inventor	HITTINGER		
		Group Art Unit	1625		
		Examiner Name	Not Yet Known		
Sheet	4	of	4	Attorney Docket Number	FRAV2003/0004 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PANDYA et al, Studies on Potential Drugs : Potential Anthelmintics Part I, J. Inst. Chemists (India), Vol. XLVII, November 1975 pp. 235-237	
		SHIZUO et al, Coloring of High Molecular Weight Material, English Language Abstract of JP 53-47439	
		SUN et al, Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound, J. Med. Chem., 1997, 40, pp. 2113-2116	
		SWELLAM et al, Emerging role of p53, bcl-2 and Telomerase Activity in Egyptian Breast Cancer Patients, Abstract of IUBMB Life, 2004, 56(8), 483-490	
		WHEELHOUSE et al, Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA, J. Am. Chem. Soc., 1998, 120, pp. 3261-3262	
		WHITTEN et al, Rapid Microscale Synthesis, a New method for Lead Optimization Using Robotics and Solution Phase Chemistry: Application to the Synthesis and Optimization of Corticotropin-Releasing Factor1 Receptor Antagonists, J. Med. Chem., 1996, 39, pp. 4354-4357	
		Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, Volume 1, 1004-1010, 1996	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.